APCs	Antigen-presenting cells
AT1/AT2	Alveolar type 1/type 2 cells
BEACON	BEACON CRC trial (encorafenib + cetuximab)
BRAF	v-Raf murine sarcoma viral oncogene homolog B1
CAF(s)	Cancer-associated fibroblast(s)
CA19-9	Carbohydrate antigen 19-9
CEA	Carcinoembryonic antigen
CRC	Colorectal cancer
ctDNA	Circulating tumor DNA
DCR	Disease control rate
EGFR	Epidermal growth factor receptor
EMT	Epithelial–mesenchymal transition
ERK	Extracellular signal-regulated kinase
GTPase	Guanosine triphosphatase
GTP	Guanosine triphosphate
GDP	Guanosine diphosphate
HRAS	Harvey rat sarcoma viral oncogene homolog
KRAS	Kirsten rat sarcoma viral oncogene homolog
MAPK	Mitogen-activated protein kinase
mCRC	Metastatic colorectal cancer
MEK	Mitogen-activated protein kinase kinase (MAP2K)
mOS	Median overall survival
mPFS	Median progression-free survival
MHC	Major histocompatibility complex
MRD	Minimal residual disease
MYC	MYC proto-oncogene
NSCLC	Non-small cell lung cancer
ORR	Objective response rate
PDAC	Pancreatic ductal adenocarcinoma
PFS	Progression-free survival
PI3K	Phosphatidylinositol-3-kinase
PROTAC	Proteolysis-targeting chimera
RAF	Rapidly accelerated fibrosarcoma kinase family
RAS	Rat sarcoma (small GTPase family)
SHP2	Src homology 2 domain-containing phosphatase 2 (PTPN11)
SOS1	Son of sevenless homolog 1
TCR	T-cell receptor
TME	Tumor microenvironment
TRAE(s)	Treatment-related adverse event(s)